Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Current Deferred Revenue: 2019-2024

Historic Current Deferred Revenue for Avidity Biosciences (RNA) over the last 6 years, with Dec 2024 value amounting to $58.9 million.

  • Avidity Biosciences' Current Deferred Revenue fell 17.33% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.2 million, marking a year-over-year decrease of 17.33%. This contributed to the annual value of $58.9 million for FY2024, which is 14.89% down from last year.
  • According to the latest figures from FY2024, Avidity Biosciences' Current Deferred Revenue is $58.9 million, which was down 14.89% from $69.3 million recorded in FY2023.
  • Avidity Biosciences' Current Deferred Revenue's 5-year high stood at $69.3 million during FY2023, with a 5-year trough of $3.7 million in FY2020.
  • Moreover, its 3-year median value for Current Deferred Revenue was $58.9 million (2024), whereas its average is $44.8 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first surged by 1,021.67% in 2023, then fell by 14.89% in 2024.
  • Avidity Biosciences' Current Deferred Revenue (Yearly) stood at $3.7 million in 2020, then skyrocketed by 31.82% to $4.9 million in 2021, then rose by 26.95% to $6.2 million in 2022, then skyrocketed by 1,021.67% to $69.3 million in 2023, then fell by 14.89% to $58.9 million in 2024.